Primary study · included by 1 review

Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial.

Jakobsen 2024 (MESRIX-III) · Jakobsen Kathrine Kronberg, Carlander Amanda-Louise Fenger, Todsen Tobias, et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Included by

Treatment of Xerostomia with Mesenchymal Stem Cells - A Systematic Review and Meta-Analysis of Clinical Trials.

Non-Cochrane · intervention · 2026 · cited as Jakobsen 2024 (MESRIX-III) · Results, Table 1; reference 27; ROB-ME supplement

Outcome this study informs	Pooled effect	Evidence	Certainty
Unstimulated whole salivary flow rate (UWS) Mesenchymal stem cell (MSC) injection into the salivary glands vs Placebo (saline, saline with albumin, or DMSO) · Short term (up to 6 months; time point closest to 4 months)	MD 0.06 [-0.05, 0.17]	3 studies · 214 participants	GRADE not reported

1 including review in total.